drugset / Trial / NCT04255017
A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
RandomizedParallel-groupSingle-blindTreatment
Summary
At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment of 2019-nCoV pneumonia by studying the efficacy of abidol hydrochloride, oseltamivir and lopinavir/ritonavir in the treatment of 2019-nCoV viral pneumonia, and to explore effective antiviral drugs for new coronavirus. To provide reliable evidence-based medicine basis for the treatment of viral pneumonia caused by new coronavirus infection.
Timeline
- Start
- 2020-02-01
- Primary completion
- 2020-06-01
- Completion
- 2020-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lopinavir | Other / unclassified | — | — |
| Subject | Oseltamivir | Small molecule | 75 mg | — |
| Subject | Ritonavir | Other / unclassified | — | — |
| Subject | Umifenovir | Small molecule | 0.2 g | — |